Quantitative Stability Evaluation of Reconstituted Azacitidine Under Clinical Storage Conditions
Authors:
- Stefano RugaSRStefano Ruga
- Renato LombardiRLRenato Lombardi
- Tonia BocciTBTonia Bocci
- Michelangelo ArmeniseMAMichelangelo Armenise
- Mara MasulloMMMara Masullo
- Chiara LamestaCLChiara Lamesta
- Roberto BavaRoberto Bava
- Fabio CastagnaFabio Castagna
- Elisa MatareseEMElisa Matarese
- Maria Pia Di ViestiMVMaria Pia Di Viesti
- Annalucia BiancofioreABAnnalucia Biancofiore
- Giovanna LiguoriGiovanna Liguori
Open Access
- 23 December 2025
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (1) , 39
Abstract
Objectives: The aim of this study was to evaluate the stability of azacitidine (AZA) under clinical storage conditions (room temperature vs. refrigeration) to identify practical protocols that minimize waste and improve cost-effectiveness. Methods: AZA solutions (1 mg/mL) were stored at 23 ± 2 °C or 4 °C. Stability was assessed using a validated high-performance liquid chromatography (HPLC) method. Chromatographic separation was achieved on a Hypersil ODS C18 column (250 mm × 4.6 mm, 5 μm) using an isocratic mobile phase of 50 mM potassium phosphate buffer (pH 7.0)-acetonitrile (98:2, v/v) at a flow rate of 1.0 mL/min, with UV detection at 245 nm and a 20 μL injection volume. The method demonstrated specificity for AZA and its main degradation product (DP), with LOD and LOQ of 12.56 μg/mL and 62.8 μg/mL, respectively. Linearity (R2 = 0.9928), precision (RSD% < 5 for mid/high levels), and accuracy (mean recovery 96%) were established. Results: Azacitidine degraded rapidly at room temperature, with >85% loss within 24 h. In contrast, refrigeration at 4 °C significantly delayed degradation, with only ~26% loss observed over the same 24 h period. Chromatographic analysis confirmed the formation of a primary degradation product (tentatively identified as the open-ring hydrolytic species N-(formylamidino)-N′-β-D-ribofuranosylurea based on its chromatographic behavior and literature data), consistent with the known hydrolytic pathway. The applied HPLC-UV method offered an optimal balance of specificity and practicality for monitoring this main degradation trend under clinical storage conditions, distinguishing it from more complex techniques used primarily for structural elucidation. Conclusions: The pronounced instability of reconstituted AZA underscores the critical importance of strict adherence to immediate-use protocols. Refrigeration provides only a limited stability window. Based on our kinetic data, maintaining the reconstituted solution within an acceptable degradation limit (e.g., ≤10% loss) at 4 °C would require administration within a very short timeframe, supporting current handling guidelines to ensure therapeutic efficacy and minimize economic waste.Keywords
This publication has 22 references indexed in Scilit:
- The epigenetic revolution in hematology: from benchside breakthroughs to clinical transformationsClinical and Experimental Medicine, 2025
- Long-term exposure and response to azacitidine for post-hematopoietic stem cell transplantation relapse of early T-cell precursor acute lymphoblastic leukemia: a case report and review of the literatureLeukemia & Lymphoma, 2024
- Voltammetric quantification, spectroscopic, and DFT studies on the binding of the antineoplastic drug Azacitidine with DNAJournal of Pharmaceutical and Biomedical Analysis, 2023
- DNA methyltransferase inhibitor exposure–response: Challenges and opportunitiesClinical and Translational Science, 2023
- Treatment in patients with acute myeloid leukemia/high‐risk myelodysplastic syndrome with hypomethylating agents: Day‐hospital management compared to home care settingEuropean Journal of Haematology, 2023
- Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPharmacoEconomics, 2023
- Mitosis as an anti-cancer targetOncogene, 2011
- Chemical Decomposition of 5-Aza-2′-deoxycytidine (Decitabine): Kinetic Analyses and Identification of Products by NMR, HPLC, and Mass SpectrometryChemical Research in Toxicology, 2009
- DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic SyndromesSeminars in Hematology, 2008
- Inhibitors of DNA methylation in the treatment of hematological malignancies and MDSClinical Immunology, 2003